Latest Conference Articles

Results from the phase 3 CAPItello-291 clinical trial show that the combination doubled the median progression-free survival compared with the placebo in patients with HR-positive, HER2-negative advanced breast cancer.

BYLieve clinical trial data indicate long-term and very-long-term data disease control was observed in 25.6% and 16.5% of patients, respectively, with PFS at 24.8 and 29.4 months in patients with HR-positive, HER2-negative advanced breast cancer.

Efficacy and safety profile in combination with alpelisib is comparable to that reported in the BYLieve and SOLAR-1 clinical trials, according to a poster presentation at the San Antonio Breast Cancer Symposium.

Pharmacy Times will be covering the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which gathers pharmacy professionals working in malignant and classical hematology in New Orleans, Louisiana.

Based on the ALIFE 2 trial results, the investigators do not advise the routine use of low-molecular-weight heparin in women with recurrent pregnancy loss and confirmed inherited thrombophilia.

Dawn L. Hershman, MD, MS, Columbia University Medical Center, New York, NY, presents her findings at the 2022 San Antonio Breast Cancer Symposium.

Researchers discovered the most common single gene mutation that causes treatment-resistance in first- line ER-positive or HER2-negative breast cancer treatment with a CDK4/6 inhibitor.

Clinical trial results found that second-line treatment with trastuzumab deruxtecan led to significantly longer overall survival compared with trastuzumab emtansine.

DESTINY-Breast02 clinical trial results show trastuzumab deruxtecan demonstrated a clinically meaningful and statistically significant improvement in progression-free and overall survival.

Breast cancer expert joined a panel to discuss aromatase inhibitors at the San Antonio Breast Cancer Symposium (SABCS) on December 6, 2022.

Future research should investigate which therapies with new mechanisms of action add incremental benefit to existing treatment regimens for non-small cell lung cancer.

When used with chemotherapy, pembrolizumab provides a synergistic response to increase survival rates.

A new radiation therapy may reduce toxicity compared to standard therapy, paving the way for a safer and possibly, more effective, treatment of early-stage breast cancer.

Kalin Clifford, associate professor in the Geriatrics Division at Texas Tech University Health Sciences Center in the Jerry H. Hodge School of Pharmacy, discusses the potential benefits of herbal supplements for dementia care.

Dena Dillon, HIV clinical pharmacy specialist at the University of Iowa Health Care, discusses 2-drug regimens for individuals living with HIV.

Jawad Saleh, clinical manager of Pharmacy Services at the Hospital for Special Surgery, discusses how pharmacists can treat postoperative nausea and vomiting.

Results of RIGHT Choice phase 2 clinical trial show Kisqali doubled PFS and showed fewer adverse events.

Biomarker testing and management of immune-related adverse events are key roles for pharmacists.

Tom Greenlee, retail pharmacy manager at the University of Missouri Health Care, and Kayla Hodges, 340B Analyst in Pharmacy Business at the University of Missouri Health Care, discuss how a successful career ladder can help retain pharmacy technicians.

Getting payers on board will be key to national biosimilar cost-savings potential.

A survey of women in New York confirmed that nearly three-quarters would be comfortable getting a contraceptive prescription from a pharmacist.

Increasing workplace diversity, addressing health disparities, and overcoming disruptions from COVID-19 are considered top goals among pharmacy stakeholders.

O’Mally Monahan, vice president of Operations at McKesson RxO, discusses patient assistant programs and how they can reduce a delay in treatment.

Pharmacists concluded that the workflow could be implemented for any drugs that are in short supply.

Michelle Condren, PharmD, AE-C, BCPPS, CDCES, FPPA, discussed pharmacists' roles in inpatient diabetes management.

Results suggest pharmacists should use the phrase “bad reaction” to avoid stigma associated with the term “overdose.”

Three key opportunities for oncology stewardship are dose rounding, implementation of biosimilars, and management of sites of care.

Implementing screening tools, conducting brief interventions, and involving pharmacists can help manage alcohol use disorder and Alcohol Withdrawal Syndrome.